Titan Pharmaceuticals Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:N/A
Industry:Biotech
Founded:N/A
Lead Investor(s):N/A

Industry Ranking

Estimated Revenue & Financials

  • Titan Pharmaceuticals's estimated annual revenue is currently $5.4M per year.
  • Titan Pharmaceuticals's estimated revenue per employee is $111,020

Employee Data

  • Titan Pharmaceuticals has 49 Employees.
  • Titan Pharmaceuticals grew their employee count by 17% last year.
  • Titan Pharmaceuticals currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$7M4510%N/A-N/A
#2
N/A205N/AN/A-N/A
#3
$46.8M3024%N/A-N/A
#4
$22.3M144N/AN/A-N/A
#5
$44.3M286N/AN/A-N/A
#6
$101.2M65346%N/A-N/A
#7
$33.3M2153%N/A-N/A
#8
$28.7M1858%N/A-N/A
#9
$39.4M254N/AN/A-N/A
#10
$6.5M4214%N/A-N/A
Missing a competitor? Contribute!?
Submit

Titan Pharmaceuticals Inc. is developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product is Probuphine®, the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. It was approved by the U.S. Food and Drug Administration in May 2016 and is being commercialized in the U.S. by partner Braeburn Pharmaceuticals. Probuphine employs Titan's proprietary drug delivery system ProNeura, which is capable of delivering sustained, consistent levels of medication for up to 12 months. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

keywords:N/A

49

Number of Employees

$5.4M

Revenue (est)

1

Current Jobs

17%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Titan Pharmaceuticals News

08/14/2019 - Titan Pharmaceuticals Reports Second Quarter 2019 ...

14, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today reported financial results for the second quarter ended June 30, 2019 and ...

09/04/2019 - Why Investors remained confident on- Titan Pharmaceuticals ...

On Tuesday, Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) reached at $0.49 price level during last trade its distance from 20 days simple ...

08/14/2019 - Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 ...

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Q2 2019 Earnings Conference Call August 14, 2019 4:30 PM ET. Company Participants.